Ryan Scott


Neoadjuvant Enfortumab Vedotin May Be an Option for Cisplatin-Ineligible MIBC

May 28th 2022

Neoadjuvant administration of the antibody drug conjugate enfortumab vedotin-ejfv represents a potential future treatment option for patients with muscle invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Fox Chase Cancer Center Experts Highlight the Growing Treatment Landscapes in Lung Cancer

May 27th 2022

Multiple FDA-approved frontline immunotherapy options have continued to shape the treatment paradigm in non–small cell lung cancer. Additionally, more knowledge regarding the effects of immunotherapy on certain driver mutations has helped drive therapy decisions across lines of treatment.

Frontline Encorafenib/Cetuximab Plus or Minus Chemo Is Under Evaluation for BRAF V600E–Mutant mCRC

May 25th 2022

The safety and efficacy of encorafenib plus cetuximab with or without standard-of-care chemotherapy will be compared with that of chemotherapy alone in patients with BRAF V600E–mutated metastatic colorectal cancer as part of the phase 3 BREAKWATER trial.

Biomarker Testing Is A Critical Component in Treatment of Gynecologic Cancers

May 25th 2022

Rebecca A. Previs, MD, discusses the role of biomarkers in uterine and endometrial cancers, the standard of care for patients with different biomarkers in uterine cancer, how PARP inhibitors have affected the treatment of ovarian cancer, and the key clinical trials in gynecologic cancers.

Poziotinib Provides Clinically Meaningful OS Benefit in Metastatic HER2+ Breast Cancer

May 25th 2022

Poziotinib prolonged overall survival in heavily pretreated Korean patients with HER2-positive metastatic breast cancer.

Emerging Chemotherapy-Free Approaches Raise Sequencing Questions in MCL Management

May 24th 2022

Martin F. Dietrich, MD, PhD, highlights recent updates in mantle cell lymphoma treatment, explains how new developments have raised sequencing questions, and projects where future research efforts will focus.

Monk Breaks Down Recent Advances Across the Gynecologic Cancer Paradigm

May 22nd 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the future of ovarian cancer treatment, ongoing and future trials, as well as combination therapies that may benefit patients with ovarian cancer, cervical cancer, and endometrial cancer.

Addressing Barriers Contributing to Disparities in CRC Screening in Underserved Populations

May 20th 2022

Denalee O'Malley, PhD, sheds light on racial and ethnic disparities in colorectal cancer screening, and strategies that can be used to address existing barriers in the clinic and beyond.

Sacituzumab Govitecan Under Further Exploration in Metastatic Urothelial Cancer

May 19th 2022

Sacituzumab govitecan will be further evaluated in patients with locally advanced unresectable or metastatic urothelial cancer that has progressed after prior platinum or checkpoint inhibitor therapy, as a part of the phase 3 TROPiCS-04 trial.

Sabizabulin Yields Encouraging rPFS, Tolerable Toxicity Profile in Previously Treated mCRPC

May 17th 2022

The utilization of sabizabulin in patients with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting therapy yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099).

Stanford Faculty Break Down Advancements in Women’s Cancer Care

May 13th 2022

Advancements in treatment options across the spectrum on women’s cancers include de-escalating therapy in HER2-positive breast cancer, using tisotumab vedotin-tftv in cervical cancer, shifting therapies to the frontline setting in endometrial cancer, and using checkpoint inhibitors in ovarian cancer.

Emerging Targeted Therapies Continue to Shift Paradigm in EGFR Exon 20–Mutated NSCLC

May 12th 2022

Edward Kim, MD, MBA, discussed the facets of each presentation from the meeting, featuring other emerging targeted therapies in NSCLC, biomarker testing in the space, frontline immunotherapy in NSCLC, and the current management of small cell lung cancer.

Pilot Study Shows Promising Results With CPX-351 in Relapsed/Refractory ALL

May 12th 2022

Bijal Shah, MD, MS, discusses the results of a phase 2 pilot study investigating CPX-351 in adults with high-risk relapsed/refractory acute lymphoblastic leukemia, as well as next steps for research in this patient population.

Targeted Therapies Continue to Expand the Treatment Paradigm in NSCLC

May 12th 2022

The treatment landscape continues to expand across non–small cell lung cancer, with the FDA approvals of multiple agents, including targeted therapies such as sotorasib and lorlatinib.

Vibostolimab/Pembrolizumab Combo Elicits Antitumor Activity in Metastatic Cervical Cancer

May 11th 2022

Two investigated doses of vibostolimab in combination with pembrolizumab resulted in comparable antitumor activity and safety in patients with locally advanced or metastatic cervical cancer who were naïve to PD-1/PD-L1 inhibitors, regardless of PD-L1 status.

Entrectinib Continues to Yield Promising Data in NTRK Fusion–Positive Breast Cancer

May 11th 2022

Entrectinib produced deep and durable responses in patients with breast cancer harboring NTRK fusions.

Nihilism Remains a Barrier to Effective Treatment Delivery in Pancreatic Cancer

May 10th 2022

Jonathan Mizrahi, MD, discusses updates from the meeting in pancreatic cancer and hepatocellular carcinoma, the growing role of immunotherapy in GI cancer, and the ‘watch and wait’ protocol seen in rectal cancer

Lower Rates of Negative Surgical Margins Found in Black Patients Vs White Patients with GI Tract Cancer

May 10th 2022

Rates of negative surgical margins and adequate lymphadenectomies were lower in Black patients with gastrointestinal tract cancer compared with White patients, according to data from a retrospective cohort study published in JAMA Network Open.

Racial Disparities Revealed in Surgical Outcomes in Gastrointestinal Tract Cancer

May 9th 2022

Sajid A. Khan MD, FACS, FSSO, discusses findings from the study on racial disparities in surgical outcomes and quality of care for GI tract cancer, plus what issues need to be addressed to close the gap in care.

PARP Inhibitors Are Under Study as Treatment Options Beyond BRCA-Mutated Breast Cancer

May 9th 2022

Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.